Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2012-11-14 Director's Dealing
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Response to ASX Query 4 pages 86.1KB
Director's Dealing Classification · 95% confidence The document is a letter from Cyclopharm Limited responding to an ASX Compliance query regarding late lodgement of Appendix 3Y notices, which relate to changes in directors' shareholdings. The content focuses on compliance with listing rules 3.19A and 3.19B about directors' disclosure obligations. Appendix 3Y is a form used to notify changes in directors' interests in shares. The document does not contain financial statements or performance data but is a regulatory compliance communication about director shareholding disclosures. This fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length (7434 characters) and detailed explanation of the late lodgement and compliance measures further support this classification. Therefore, the filing type is DIRS with high confidence.
2012-11-14 English
Renounceable Issue 2 pages 64.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement by Cyclopharm Limited regarding a fully underwritten pro-rata renounceable entitlement offer to raise approximately A$2.1 million. It details the terms of the rights issue, the timetable for the offer, and the intended use of proceeds. There are no financial statements or detailed financial performance data included. The document is focused on capital raising activities and changes in the company's capital structure. It is not a full financial report, audit report, or earnings release. Given the content and purpose, this document fits the category of Capital/Financing Update (CAP). The document length is 3571 characters, which is consistent with an announcement rather than a full report.
2012-11-08 English
Letter to Eligible Shareholders 3 pages 40.6KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about a capital raising through a pro-rata entitlement offer (rights issue) by Cyclopharm Limited. It includes specifics about the number of shares to be issued, pricing, underwriting, eligibility, important dates, and the purpose of the funds raised. There is no financial statement or report content, but rather an update on financing activities and capital structure changes. This fits the definition of a Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about the financing event, not just a brief notice or a report publication announcement.
2012-11-08 English
Letter to Ineligible Shareholders 2 pages 38.6KB
Capital/Financing Update Classification · 95% confidence The document is a letter to shareholders dated 9 November 2012 announcing a pro-rata entitlement offer (Rights Issue) to raise capital. It details the terms of the Rights Issue, underwriting, eligible shareholders, important dates, and the purpose of the capital raising. There are no financial statements or detailed financial performance data included. The document is an announcement of a capital raising event and not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4226 characters, which is consistent with an announcement rather than a full report.
2012-11-08 English
Offer Booklet 11 pages 65.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Renounceable rights issue Offer Booklet' and details a capital raising by way of a renounceable pro-rata entitlement offer to existing shareholders. It includes information about the offer price, record date, underwriting, key dates, and instructions for shareholders on how to participate. The content is focused on the terms and mechanics of a rights issue, which is a capital raising activity. There are no financial statements or earnings data presented, nor is this a report or announcement of voting results or management changes. The document is a detailed offer booklet related to a capital raising event, which fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the offer document itself, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2012-11-08 English
Appendix 3B 9 pages 112.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about a new issue of fully paid ordinary shares, including the number of shares, issue price, purpose of the issue, rights issue details, record dates, underwriting information, and quotation application to the ASX. It references ASX rules and the Corporations Act, indicating it is a formal announcement related to capital raising and securities issuance. The content is consistent with a capital/financing update rather than a full financial report or other filing types. The document length is over 13,000 characters and contains substantive details about the share issue, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-11-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.